Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2022-45793
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
Executable files writable by low-privileged users in Omron Sysmac Studio
Source: NVD (National Vulnerability Database)
Vulnerability Description
Sysmac Studio installs executables in a directory with poor permissions. This can allow a locally-authenticated attacker to overwrite files which will result in code execution with privileges of a different user.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N
Source: NVD (National Vulnerability Database)
Vulnerability Type
缺省权限不正确
Source: NVD (National Vulnerability Database)
Vulnerability Title
Omron Sysmac Studio 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Omron Sysmac Studio是日本欧姆龙(Omron)公司的一个独特的环境,它将逻辑、运动和驱动、机器人、安全、可视化、传感和信息技术集成在一个项目中,从而降低了学习曲线和术中软件成本。 Omron Sysmac Studio 1.54版本及之前版本存在安全漏洞,该漏洞源于授权管理不当。攻击者利用该漏洞可以执行任意代码。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
OmronSysmac Studio 0 ~ 1.54.0 -
II. Public POCs for CVE-2022-45793
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2022-45793
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2022-45793

No comments yet


Leave a comment